91 related articles for article (PubMed ID: 2642607)
1. Structural differences between a ras oncogene protein and the normal protein.
Tong LA; de Vos AM; Milburn MV; Jancarik J; Noguchi S; Nishimura S; Miura K; Ohtsuka E; Kim SH
Nature; 1989 Jan; 337(6202):90-3. PubMed ID: 2642607
[TBL] [Abstract][Full Text] [Related]
2. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression.
Al-Mulla F; Milner-White EJ; Going JJ; Birnie GD
J Pathol; 1999 Mar; 187(4):433-8. PubMed ID: 10398103
[TBL] [Abstract][Full Text] [Related]
3. Structure and function of p21 ras proteins.
Shih TY; Hattori S; Clanton DJ; Ulsh LS; Chen ZQ; Lautenberger JA; Papas TS
Gene Amplif Anal; 1986; 4():53-72. PubMed ID: 3333361
[TBL] [Abstract][Full Text] [Related]
4. The Saccharomyces cerevisiae gene product SDC25 C-domain functions as an oncoprotein in NIH3T3 cells.
Barlat I; Schweighoffer F; Chevallier-Multon MC; Duchesne M; Fath I; Landais D; Jacquet M; Tocque B
Oncogene; 1993 Jan; 8(1):215-8. PubMed ID: 7999142
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics simulations of Gly-12-->Val mutant of p21(ras): dynamic inhibition mechanism.
Futatsugi N; Tsuda M
Biophys J; 2001 Dec; 81(6):3483-8. PubMed ID: 11721009
[TBL] [Abstract][Full Text] [Related]
6. Regional polysterism in the GTP-bound form of the human c-Ha-Ras protein.
Ito Y; Yamasaki K; Iwahara J; Terada T; Kamiya A; Shirouzu M; Muto Y; Kawai G; Yokoyama S; Laue ED; Wälchli M; Shibata T; Nishimura S; Miyazawa T
Biochemistry; 1997 Jul; 36(30):9109-19. PubMed ID: 9230043
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the computed structures for the phosphate-binding loop of the p21 protein containing the oncogenic site Gly 12 with the X-ray crystallographic structures for this region in the p21 protein and EFtu. A model for the structure of the p21 protein in its oncogenic form.
Chen JM; Lee G; Murphy RB; Carty RP; Brandt-Rauf PW; Friedman E; Pincus MR
J Biomol Struct Dyn; 1989 Apr; 6(5):859-75. PubMed ID: 2686707
[TBL] [Abstract][Full Text] [Related]
8. Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets.
Moodie SA; Paris M; Villafranca E; Kirshmeier P; Willumsen BM; Wolfman A
Oncogene; 1995 Aug; 11(3):447-54. PubMed ID: 7630628
[TBL] [Abstract][Full Text] [Related]
9. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation.
Pai EF; Kabsch W; Krengel U; Holmes KC; John J; Wittinghofer A
Nature; 1989 Sep; 341(6239):209-14. PubMed ID: 2476675
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
Spandidos DA
Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
[TBL] [Abstract][Full Text] [Related]
11. Crystal structures at 2.2 A resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP.
Tong LA; de Vos AM; Milburn MV; Kim SH
J Mol Biol; 1991 Feb; 217(3):503-16. PubMed ID: 1899707
[TBL] [Abstract][Full Text] [Related]
12. The binding of guanine nucleotide to N-ras p21--a phosphorous and proton magnetic resonance study.
Grand RJ; Levine BA; Byrd PJ; Gallimore PH
Oncogene; 1989 Mar; 4(3):355-61. PubMed ID: 2649849
[TBL] [Abstract][Full Text] [Related]
13. The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress.
Velasco JA; Avila MA; Notario V
Oncogene; 1999 Jan; 18(3):689-701. PubMed ID: 9989819
[TBL] [Abstract][Full Text] [Related]
14. Characterization of monoclonal antibodies specific to the activated ras p21 with aspartic acid at position 13.
La Vecchio JA; Hamer PJ; Ng SC; Trimpe KL; Carney WP
Oncogene; 1990 Aug; 5(8):1173-8. PubMed ID: 2202949
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the GTPase-activating domain of human p120GAP and implications for the interaction with Ras.
Scheffzek K; Lautwein A; Kabsch W; Ahmadian MR; Wittinghofer A
Nature; 1996 Dec; 384(6609):591-6. PubMed ID: 8955277
[TBL] [Abstract][Full Text] [Related]
16. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro.
Warne PH; Viciana PR; Downward J
Nature; 1993 Jul; 364(6435):352-5. PubMed ID: 8332195
[TBL] [Abstract][Full Text] [Related]
17. The ras gene family.
Lowy DR; Willumsen BM
Cancer Surv; 1986; 5(2):275-89. PubMed ID: 3096566
[TBL] [Abstract][Full Text] [Related]
18. High-frequency 94 GHz ENDOR characterization of the metal binding site in wild-type Ras x GDP and its oncogenic mutant G12V in frozen solution.
Bennati M; Hertel MM; Fritscher J; Prisner TF; Weiden N; Hofweber R; Spörner M; Horn G; Kalbitzer HR
Biochemistry; 2006 Jan; 45(1):42-50. PubMed ID: 16388579
[TBL] [Abstract][Full Text] [Related]
19. Rasp21 sequences opposite the nucleotide binding pocket are required for GRF-mediated nucleotide release.
Leonardsen L; DeClue JE; Lybaek H; Lowy DR; Willumsen BM
Oncogene; 1996 Nov; 13(10):2177-87. PubMed ID: 8950985
[TBL] [Abstract][Full Text] [Related]
20. Genetic and biochemical analysis of ras p21 structure.
McCormick F; Levenson C; Cole G; Innis M; Clark R
Symp Fundam Cancer Res; 1986; 39():137-42. PubMed ID: 3321304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
